If you have been reading about Synaptogenesis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-16. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
In early April 2024, the US Food and Drug Administration (FDA) approved Ceftobiprole for the treatment of adults with Staphylococcus aureus bloodstream infections (bacteremia) and for adult patients with right-sided infective endocarditis. In addition, the FDA approved Ceftobiprole for the treatment of acute bacterial skin and skin structure infections in adult patients and in adult and pediatric patients aged three months to less than 18 years with community-acquired bacterial pneumonia (CAPB).
== Discovery == Identification of the 5-HT3 receptor did not take place until 1986, lacking selective pharmacological tools. However, with the discovery that the 5-HT3 receptor plays a prominent role in chemotherapy- and radiotherapy-induced vomiting, and the concomitant development of selective 5-HT3 receptor antagonists to suppress these side effects aroused intense interest from the pharmaceutical industry and therefore the identification of 5-HT3 receptors in cell lines and native tissues quickly followed.
===== Direct method ===== The first commercially successful decaffeination process was invented by German merchant Ludwig Roselius and co-workers in 1903, after Roselius observed that a consignment of coffee beans accidentally soaked in sea water had lost most of their caffeine content while losing little of their flavour. The process was patented in 1906, and involved steaming coffee beans with various acids or bases, then using benzene as a solvent to remove the caffeine. Coffee decaffeinated this way was sold as Kaffee HAG after the company name Kaffee Handels-Aktien-Gesellschaft (Coffee Trading Company) in most of Europe, as Café Sanka in France and later as Sanka brand coffee in the United States. Café HAG and Sanka are now worldwide brands of Kraft Foods.
Alternatively, if the desired aptamer function is in vivo protein or whole cell binding for potential therapeutic or diagnostic application, incubation buffer conditions similar to in vivo plasma salt concentrations and homeostatic temperatures are more likely to generate aptamers that can bind in vivo. Another consideration in incubation buffer conditions is non-specific competitors. If there is a high likelihood of non-specific oligonucleotide retention in the reaction conditions, non specific competitors, which are small molecules or polymers other than the SELEX library that have similar physical properties to the library oligonucleotides, can be used to occupy these non-specific binding sites. Varying the relative concentration of target and oligonucleotides can also affect properties of the selected aptamers. If a good binding affinity for the selected aptamer is not a concern, then an excess of target can be used to increase the probability that at least some sequences will bind during incubation and be retained. However, this provides no selective pressure for high binding affinity, which requires the oligonucleotide library to be in excess so that there is competition between unique sequences for available specific binding sites.
Sources: en.wikipedia.org
Two examples of this are the US Navy's Grumman E-2 Hawkeye and the US Air Force's Boeing E-3 Sentry. Both were used in command and control area of operations. These systems provided essential communications links between air, ground, and naval forces. It is one of several reasons coalition forces dominated the air war. American-made color photocopiers were used to produce some of Iraq's battle plans. Some of the copiers contained concealed high-tech transmitters that revealed their positions to American electronic warfare aircraft, leading to more precise bombings.
==== X-rays ==== The earliest changes demonstrable by plain X-ray shows erosions and sclerosis in sacroiliac joints. Progression of the erosions leads to widening of the joint space and bony sclerosis. X-ray spine can reveal squaring of vertebrae with bony spur formation called syndesmophyte. This causes the "bamboo spine" appearance. A drawback of X-ray diagnosis is the signs and symptoms of AS have usually been established as long as 7–10 years prior to X-ray-evident changes occurring on a plain film X-ray, which means a delay of as long as 10 years before adequate therapies can be introduced. Options for earlier diagnosis are tomography and MRI of the sacroiliac joints, but the reliability of these tests is still unclear.
== Reconstitution in 1986 == The passenger transport authority was reconstituted by the Local Government Act 1985 in 1986 to replace the Greater Manchester County Council which was abolished. Its membership was made up of appointed councillors from the councils in Greater Manchester, based on population: Bolton 3, Bury 2, Manchester 5, Oldham 3, Rochdale 2, Salford 3, Stockport 3, Tameside 3, Trafford 3, and Wigan 3.
A depsipeptide is a peptide in which one or more amide, -C(O)NHR-, linkages are replaced by the corresponding ester, -C(O)OR-. Depsipeptides usually contain alternating amide and ester linkages. Elimination of an amide linkage in a peptide structure results in a decrease of H-bonding capability, which is responsible for secondary structure within peptides, thus inducing structural warping and diversity. Because of the decreased electron delocalization in esters relative to amides, depsipeptides have lower rotational barriers and therefore are quite flexible and malleable structures. They are mainly produced in nature by soil and marine sediment inhabiting bacteria.
coli bacteria stores proteins and pyrophosphates in its periplasmic membrane until either are needed within the cell. Recent advancement in phosphoproteomic identification has resulted in the discoveries of countless phosphorylation sites in proteins. This required an integrative medium for accessible data in which known phosphorylation sites of proteins are organized. A curated database of dbPAF was created, containing known phosphorylation sites in H. sapiens, M. musculus, R. norvegicus, D. melanogaster, C. elegans, S. pombe and S. cerevisiae. The database currently holds 294,370 non-redundant phosphorylation sites of 40,432 proteins. Other tools of phosphorylation prediction in proteins include NetPhos for eukaryotes, NetPhosBac for bacteria, and ViralPhos for viruses.
Sources: en.wikipedia.org
==== MPP salary increase and pension re-introduction ==== In 2025, Ford's government introduced legislation to grant MPPs a 35 per cent pay raise. Previously, an MPP earned $116,550 annually, which had not changed since 2009. With support from the other parties, the Legislature enacted the MPP Pension and Compensation Act, 2025, which increased MPPs' salaries to $157,350, ministers from $165,851 to $223,909, and the premier from $208,974 to $282,129. The change also re-introduced pensions for MPPs.
Hydrogen Peroxide at The Periodic Table of Videos (University of Nottingham) Material Safety Data Sheet ATSDR Agency for Toxic Substances and Disease Registry FAQ International Chemical Safety Card 0164 NIOSH Pocket Guide to Chemical Hazards Process flow sheet of Hydrogen Peroxide Production by anthrahydroquinone autoxidation Hydrogen Peroxide Handbook by Rocketdyne IR spectroscopic study J. Phys. Chem. Bleaching action of Hydrogen peroxide at YouTube
AdventHealth Polk South, Inc. (doing business as AdventHealth Lake Wales) is a non-profit hospital campus in Lake Wales, Florida, United States owned by AdventHealth. The medical facility is a tertiary and primary stroke center that has multiple specialties. It was purchased from Community Health Systems in May 2019.
=== Sugar profile === Honey is mainly fructose (51% of sugars) and glucose (44%) (table), with remaining sugars including galactose, maltose, and sucrose, each supplying 3% or less of total sugars (table, USDA reference). The glycemic index of honey has a possible range of 31–78, depending on the variety. The specific composition, color, aroma, and flavor of any batch of honey depend on the flowers foraged by bees that produced the honey.
=== Genome === Chinese scientists published a draft genome of Ginkgo biloba in 2016. The tree has a large genome of 10.6 billion DNA nucleobase "letters" (the human genome has three billion) and about 41,840 predicted genes which enable a considerable number of antibacterial and chemical defense mechanisms. 76.58% of the assembled sequence turned out to be repetitive sequences. In 2020, a study in China of ginkgo trees up to 667 years old showed little effects of aging, finding that the trees continued to grow with age and displayed no genetic evidence of senescence, and continued to make phytochemicals indefinitely.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.